Beam Therapeutics Inc. (BEAM) Earnings
Beam Therapeutics Inc. is expected to report next earnings on August 4, 2026 (in NaN days), with a consensus EPS estimate of $-1.11. BEAM has beaten EPS estimates in 4 of its last 9 reported quarters (average surprise +86.4% over the last four).
| Report date | EPS est | EPS actual | Surprise | Revenue | Rev. surprise |
|---|---|---|---|---|---|
| May 7, 2026 | $-0.87 | $-0.91 | -4.6% | $32M | +189.1% |
| Feb 24, 2026 | $-1.13 | $-0.10 | +91.2% | $114M | +970.0% |
| Nov 4, 2025 | $-0.98 | $-1.10 | -12.2% | $10M | -26.6% |
| Feb 27, 2024 | $-1.01 | $1.73 | +271.3% | $316M | +1593.6% |
| Feb 28, 2023 | $-1.32 | $-0.54 | +59.1% | $20M | +57.6% |
| Feb 28, 2022 | $-1.02 | $-0.85 | +16.7% | $51M | +496.4% |
| Aug 10, 2021 | $-0.58 | $-0.95 | -63.8% | $6000 | +11.6% |
| Mar 15, 2021 | $-0.70 | $-0.72 | -2.9% | $6000 | — |
| Aug 12, 2020 | $-0.56 | $-0.69 | -23.2% | $6000 | +30.2% |
| Feb 7, 2020 | — | $-0.54 | — | $6000 | — |
| Jun 29, 2019 | — | $-0.51 | — | $6000 | — |
Source: company filings + earnings calendar. For informational purposes only — not investment advice.
Earnings call summary
Q4 FY2025 · February 24, 2026
AI summary of management’s prepared remarks and analyst Q&A. For informational purposes only — not investment advice.
Management highlights
John Evans introduced Beam's vision of providing lifelong cures using base editing. Beam is expanding its pipeline with a new development program for PKU (BEAM-304) leveraging base editing and LNP delivery. Amy Simon detailed PKU's clinical manifestations and unmet needs. Gopi Shanker discussed the base editing approach for BEAM-304 and early preclinical data. Kiran Musunuru shared insights on PKU variants and regulatory interactions. Sravan Emany announced a strategic financing agreement to support risto-cel's commercialization and strengthen the balance sheet.
Guidance
Anticipate filing IND for BEAM-304 in 2026, report initial BEAM-301 data in GSDIa, complete BEAM-103 healthy volunteer study, and continue advancing in vivo HSC editing. Look forward to submitting risto-cel BLA as early as year-end and accelerating the path to approval for lead programs.
Analyst Q&A
Q: Talked about regulatory path forward and addressing multiple mutations in PKU, and strategic financing impact on reallocating capital.
A: Gopi mentioned research underway for other mutations with fast timelines, Amy spoke about FDA collaboration and adaptive trial design, Sravan said financing provides flexibility for commercial launch and pipeline growth.
Q: Questions on IP for R408W and LNP delivery in 304.
A: John said Beam has access to necessary IP, and 304 uses similar LNP approaches as 302, 301 with internal ionizable lipids.
Q: Questions on FDA draft guidance for individualized therapy and PKU mutations, 304 guide RNAs and bystander editing.
A: Kiran discussed FDA interactions and plausible mechanism framework, Gopi talked about unique guide RNAs for mutations and confident bystander profile.
Q: Question on sickle cell market share assumptions for risto-cel.
A: Giuseppe Ciaramella talked about market demand, risto-cel's manufacturing process optimization.
Q: Questions on AATD upcoming readout and pivotal.
A: John talked about data update on 302, dosing schedule, efficacy, safety, and durability.
Q: Questions on PKU patient responses to current options and Phase I/II age range.
A: Amy said R408W patients don't respond well to current options, and FDA collaborative on age range recruitment.
Q: Questions on A1AT, GSK returning rights, and U.S. enrollment for pivotal.
A: John didn't comment on GSK but said BEAM-302 has best-in-class data, and U.S. enrollment part is premature.
Q: Question on PKU patient mutation copies and Phase I/II design.
A: Gopi said one copy correction sufficient, and Amy talked about age range recruitment.
Q: Questions on PKU editing rate vs other diseases and OpEx for PKU program.
A: Gopi explained low threshold for PKU editing, Sravan said PKU is in runway guidance and cost balanced across portfolio.
Q: Questions on plausible mechanism pathway for AATD and LNP safety for PKU.
A: John said plausible mechanism not necessary for AATD traditional path, and Beam has expertise in LNP for PKU.
Q: Question on next-gen sickle cell program prioritization.
A: Giuseppe Ciaramella talked about in vivo program's ease of delivery and progress.
Q: Question on 103 healthy volunteers and in vivo editing efficiencies.
A: Giuseppe Ciaramella talked about 103's antibody component and comparable editing efficiencies